Sign in
Taking people in South AfricaPhase 3

Tests nemtabrutinib with venetoclax in adults with relapsed chronic lymphocytic leukemia

Tests nemtabrutinib plus venetoclax in adults with returning chronic lymphocytic leukemia.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Cape Town, Kuilsriver, and Pretoria, South AfricaSee the 3 sitesAlso in 22 other countries, 104 sites
Trial code
Registry title
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Status
Recruiting
Phase
Phase 3
People taking part
735 people, planned
Started
8 Aug 2023
Expected to end
1 Jul 2035
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Nemtabrutinib
  • Venetoclax
  • Rituximab
Record updated
17 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma whose disease came back or did not respond to at least 1 earlier treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
Confirmed CLL/SLL with active disease that needs treatment. The disease came back or did not respond to at least 1 earlier therapy. At least 1 marker of disease burden. ECOG performance status 0 to 2. Life expectancy of at least 3 months.
Earlier treatment
Must have had at least 1 earlier therapy. Cannot join if they had earlier anticancer therapy within 5 half-lives or 4 weeks (for a monoclonal antibody) before randomization, or a BCL2 inhibitor within 12 months before randomization.
Biomarker or test result
Del(17p) status, TP53 mutation status and IGHV mutation status results are needed before randomization for Part 2 participants only.

Main reasons for not taking part

  • Active hepatitis B or hepatitis C infection
  • Richter transformation or active central nervous system involvement by CLL/SLL
  • Another cancer that is getting worse or needed treatment in the past 2 years
  • Active infection needing systemic therapy during screening
  • Clinically significant heart disease or a severe bleeding disorder

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Confirmed diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and active disease clearly documented to initiate therapy
  • Deletion (Del) (17p) status, tumor protein 53 (TP53) mutation status, and immunoglobulin heavy chain gene (IGHV) mutation status results required before randomization for Part 2 participants only
  • Relapsed or refractory to at least 1 prior available therapy
  • Have at least 1 marker of disease burden
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization
  • Has a life expectancy of at least 3 months
  • Has the ability to swallow and retain oral medication
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening
  • Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria
  • Participants with adequate organ function with specimens collected within 7 days before the start of study intervention
  • If capable of producing sperm, participant agrees to eliminate Nemtabrutinib: 12 days, Venetoclax: 1 month (30 days), Rituximab (rituximab biosimilar): not applicable; abstains from penile-vaginal intercourse as their preferred and usual lifestyle; OR uses prescribed contraception
  • Participant assigned female sex at birth are eligible to participate if not pregnant or breastfeeding and are not a person of childbearing potential (POCBP) OR is a POCBP and uses a contraceptive method that is highly effective, has a negative highly sensitive pregnancy test, and abstains from breastfeeding

Who cannot take part

  • Has gastrointestinal (GI) dysfunction that may affect drug absorption
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease and/or acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening
  • Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before randomization
  • Has received prior B-cell lymphoma 2 inhibitor(s) (BCL2i) within ≤ 12 months before randomization or has received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids
  • Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors
  • Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention
  • Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration
  • Participants who have not adequately recovered from major surgery or have ongoing surgical complications
  • Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection
  • Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
  • Has an active infection requiring systemic therapy, such as intravenous (IV) antibiotics, during screening
  • Clinically significant cardiovascular disease
  • Has a known allergy/sensitivity to nemtabrutinib or contraindication to venetoclax/rituximab (or rituximab biosimilar), or any of the excipients
  • Has history of severe bleeding disorders (eg, hemophilia)
  • Has a known psychiatric or substance use disorder that would interfere with the participant's ability to cooperate with the requirements of the study
  • Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL

This trial is currently available in South Africa.

Also in 22 other countries, 104 sites

  • Groote Schuur Hospital (Site 4400)Cape Town, South AfricaContact: Study CoordinatorTaking people
  • Haemalife (Site 4407)Kuilsriver, South AfricaContact: Study CoordinatorTaking people
  • Alberts Cellular Therapy. (Site 4401)Pretoria, South AfricaContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).

The 2 groups in the trial

  • Nemtabrutinib + VenetoclaxTreatment being tested

    Participants will receive nemtrabrutinib oral tablets at specified doses daily starting at Cycle 1 Day 1 (C1D1) and venetoclax oral tablets at doses of 20 mg up to 400 mg daily starting at Cycle 2 Day 1 (C2D1) up to 2 years post C2D1 or until progressive disease (PD) or discontinuation. A cycle = 4 weeks.

    Treatment: Nemtabrutinib and Venetoclax

  • Venetoclax + RituximabExisting treatment, for comparison

    Participants will receive venetoclax oral tablets at doses from 20 mg up to 400 mg daily starting at C1D1 on 4-week cycles up to 2 years and rituximab or biosimilar at 375 mg/m\^2 up to 500 mg/m2 intravenous infusion once per 28-day cycle starting at C2D1, for 6 total cycles. Treatment will continue until progressive disease (PD) or discontinuation.

    Treatment: Venetoclax and Rituximab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
Plain-language title
Tests nemtabrutinib with venetoclax in adults with relapsed chronic lymphocytic leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 November 2026